DOCSLIB.ORG

Frontiers in Dermatology and Venereology - a Series of Theme Issues in Relation to the 100-Year Anniversary of Actadv

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Frontiers in Dermatology and Venereology - a Series of Theme Issues in Relation to the 100-Year Anniversary of Actadv ISSN 0001-5555 ActaDV Volume 100 2020 Theme issue ADVANCES IN DERMATOLOGY AND VENEREOLOGY A Non-profit International Journal for Interdisciplinary Skin Research, Clinical and Experimental Dermatology and Sexually Transmitted Diseases Frontiers in Dermatology and Venereology - A series of theme issues in relation to the 100-year anniversary of ActaDV Official Journal of - European Society for Dermatology and Psychiatry Affiliated with - The International Forum for the Study of Itch Immediate Open Access Acta Dermato-Venereologica www.medicaljournals.se/adv ACTA DERMATO-VENEREOLOGICA The journal was founded in 1920 by Professor Johan Almkvist. Since 1969 ownership has been vested in the Society for Publication of Acta Dermato-Venereologica, a non-profit organization. Since 2006 the journal is published online, independently without a commercial publisher. (For further information please see the journal’s website https://www. medicaljournals.se/acta) ActaDV is a journal for clinical and experimental research in the field of dermatology and venereology and publishes high- quality papers in English dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of review articles in special areas, as well as Correspondence to the Editor to stimulate debate. New books are also reviewed. The journal has rapid publication times. Editor-in-Chief: Olle Larkö, MD, PhD, Gothenburg Former Editors: Johan Almkvist 1920–1935 Deputy Editors: Sven Hellerström 1935–1969 Anette Bygum, MD, PhD, Odense Nils Thyresson 1969–1987 Magnus Lindberg, MD, PhD, Örebro Lennart Juhlin 1987–1999 Elisabet Nylander, MD, PhD, Umeå Anders Vahlquist 1999–2017 Kaisa Tasanen-Määttä, MD, PhD, Oulu Artur Schmidtchen 2018–2019 Section Editors: Tasuku Akiyama, Miami (Neurodermatology and Itch - Experimental) Annamari Ranki, Helsinki (Cutaneous lymphoma) Nicole Basset-Seguin, Paris (Skin cancer) Artur Schmidtchen, Lund (Wound healing and Innate immunity) Veronique Bataille, London (Melanoma, Naevi, Photobiology) Matthias Schmuth, Innsbruck (Genodermatoses and Keratinizing disorders, Josip Car, Singapore (Health Services Research and e-Health) Ichthyosis and Retinoids) Brigitte Dréno, Nantes (Acne and Rosacea) Lone Skov, Hellerup (Psoriasis) Regina Fölster-Holst, Kiel (Paediatric dermatology, Atopy and Parasitoses) Enikö Sonkoly, Stockholm (Psoriasis and related disorders) Jürg Hafner, Zürich (Skin cancer, Skin tumours, and Melanoma) Jacek Szepietowski, Wrocław (Psychodermatology) Jürgen Harder, Kiel (Cutaneous innate defense, Skin microbe interactions) Elke Weisshaar, Heidelberg (Itch and Neurodermatology) Roderick Hay, London (Cutaneous Infections) Margitta Worm, Berlin (Atopic dermatitis and Immunology) Kristian Kofoed, Copenhagen (STD and Microbiology) Claus Zachariae, Hellerup (Contact dermatitis, Acute dermatology) Veli-Matti Kähäri, Turku (Skin cancer) Magnus Ågren, Copenhagen (Wound healing & Extracellular matrix) Dennis Linder, Graz/Padua (Psychoderm., Dermato -epidemiology, e-Health) Advisory Board: Masashi Akiyama, Nagoya Rudolf Happle, Freiburg Lisa Naysmith, Edinburgh Mona Ståhle, Stockholm Wilma Bergman, Leiden Lars Iversen, Aarhus Jonathan Rees, Edinburgh Sonja Ständer, Münster Tilo Biedermann, Munich Peter van de Kerkhof, Nijmegen Jean Revuz, Paris Jouni Uitto, Philadelphia Magnus Bruze, Malmö Irene Leigh, Dundee Johannes Ring, Munich Shyam Verma, Vadodara Earl Carstens, Davis John McGrath, London Matthias Ringkamp, Baltimore Gil Yosipovitch, Miami Thomas Diepgen, Heidelberg Maja Mockenhaupt, Freiburg Inger Rosdahl, Linköping Giovanna Zambruno, Rome Charlotta Enerbäck, Linköping Dedee Murrell, Sydney Thomas Ruzicka, Munich Christos C. Zouboulis, Dessau Kilian Eyerich, Stockholm All correspondence concerning manuscripts, editorial matters and subscription should be addressed to: Acta Dermato-Venereologica S:t Johannesgatan 22, SE-753 12 Uppsala, Sweden Editorial Manager, Mrs Agneta Andersson Editorial Assistant: Ms Anna-Maria Andersson Please send an E-mail Please send an E-mail Information to authors: Acta Dermato-Venereologica publishes papers/reports on scientific investigations in the field of dermatology and venereology, as well as reviews. Case reports and good preliminary clinical trials or experimental investigations are usually published as Short Communications. However, if such papers are of great news value they could still be published as full articles. Special contributions such as extensive feature articles and proceedings may be published as supplements to the journal. For detailed instructions to authors see https://www.medicaljournals.se/acta/instructions-to-author. Publication information: Everything is Open Access and no subscription fee. For publication fees: see https://www.medicaljournals.se/acta/ instructions-to-author. Indexed in: See https://www.medicaljournals.se/acta/about/adv. Frontiers in Dermatology and Venereology DV Centenary theme issues in Volume 100 of Acta Dermato-Venereologica a t An overview c A Current issue Blistering skin disorders Theme editor: Kaisa Tasanen • Skin Fragility: Perspectives on Evidence-based Therapies, L. Bruckner-Tuderman • Collagen XVII Processing and Blistering Skin Diseases, W. Nishie • Drug Development in Pemphigoid Diseases, K. Bieber, R.J. Ludwig • Current Concepts of Dermatitis Herpetiformis, T. Salmi, K. Hervonen • Bullous Drug Reactions, M. Mockenhaupt enereologica V Forthcoming issues ermato- Genodermatoses D Theme editors: Anette Bygum and Matthias Schmuth cta • Ichthyosis: A Road Model for Skin Research, A. Vahlquist, H Törmä A • An Early Description of a “Human Mosaic” Involving the Skin: A Story from 1945, R. Happle • Dental Manifestations of Ehlers-Danlos Syndromes – A Systematic Review, I. Kapferer-Seebacher, D. Schnabl, J. Zschocke, F. M. Pope • Diagnosis and Management of Inherited Palmoplantar Keratodermas, B.R. Thomas, E.A. O’Toole • Molecular Genetics of Keratinization Disorders - What’s New, • E. Denayer, E. Legius V • Genetics of Inherited Ichthyoses and Related Diseases, J. Fischer, E. Bourrat • H. Bonnekoh, M. Butze, T. Kallinich, N. D Kambe, G. Kokolakis, K. Krause a t c Skin malignancies A Theme editors: Veronique Bataille and Nicole Basset Seguin Content details TBA Atopic dermatitis Theme editors: Magnus Lindberg and Carl-Fredrik Wahlgren Content details TBA Cutaneous and genital infections Theme editors: Roderick Hay and Kristian Kofoed Content details TBA dvances in dermatology and venereology A Previous issues Itch and pruritic disorders DV Theme editors: Elke Weisshaar, Tasuku Akiyama and Jacek Szepietowski cta • The Challenge of Basic Itch Research, E. Carstens, T. Follansbee, M.I. Carstens • Mechanisms and Management of Itch in Dry Skin, C. Sagita Moniaga, M. Tominaga, K. Takamori A • Non-dermatological Challenges of Chronic Itch, A.E. Kremer, T. Mettang, E. Weisshaar • Itch and Psyche: Bilateral Associations, R. Reszke, J.C. Szepietowski • A New Generation of Treatments for Itch, E. Fowler, G. Yosipovitch • Challenges in Clinical Research and Care in Pruritus, M.P. Pereira, C. Zeidler, M. Storck, K. Agelopoulos, W.D. Philipp-Dormston, A.G.S. Zink, S. Ständer Psoriasis Theme editors: Lone Skov and Enikö Sonkoly • Psoriasis and Genetics, N. Dand, S. Mahil, F. Capon, C.H. Smith, M.A. Simpson and J. Barker enereologica • The Woronoff Ring in Psoriasis and the Mechanisms of Postinflammatory Hypopigmentation, J. Prinz V • Psoriasis and Treatment: Past, Present and Future Aspects, C. Reid, C.E.M. Griffiths • Psoriasis and Co-morbidity, M. Amin, E.B. Lee, T-F. Tsai, J.J. Wu • Pustular Psoriasis: the Dawn of a New Era, H. Bachelez ermato- D cta A DV cta A dvances in dermatology and venereology A Theme issue: Blistering skin disorders DV cta A enereologica V BLISTERING SKIN DISORDERS ermato- D Theme Editor: cta A Kaisa Tasanen DV cta A TABLE OF CONTENTS Skin Fragility: Perspectives on Evidence-based Therapies, L. Bruckner-Tuderman 94–101 Collagen XVII Processing and Blistering Skin Diseases, W. Nishie 102–107 Drug Development in Pemphigoid Diseases, K. Bieber, R.J. Ludwig 108–114 Current Concepts of Dermatitis Herpetiformis, T. Salmi, K. Hervonen 115–121 Bullous Drug Reactions, M. Mockenhaupt 122–134 dvances in dermatology and venereology A Centenary theme section: BLISTERING SKIN DISORDERS REVIEW ARTICLE DV Skin Fragility: Perspectives on Evidence­based Therapies cta Leena BRUCKNER-TUDERMAN Department of Dermatology, Medical Faculty and Medical Center – University of Freiburg, Freiburg, Germany A The term skin fragility disorders describes a group of SIGNIFICANCE conditions in which the structural integrity of the skin is compromised and its resistance to external shear The term skin fragility describes skin that blisters and forces diminished. Skin fragility can have different cau- breaks easily upon mild friction or trauma. Skin fragility ses, ranging from genetic variations to inflammatory can have many causes, ranging from genetic variants to a or physical phenomena. The genetic skin fragility dis- compromised immune system, infections or adverse drug orders, collectively called epidermolysis bullosa, serve reactions. Studies of genetic skin fragility disorders, such enereologica as a paradigm for the study of causes and mechanisms as epidermolysis bullosa, have provided better understan- V of skin fragility. Recent biomedical research has revea- ding of their causes and mechanisms. At least 20 genes led substantial genetic heterogeneity of the epidermo- may be involved in
Load more

Recommended publications
  • Update on Challenging Disorders of Pigmentation in Skin of Color Heather Woolery-Lloyd, M.D
    Update on Challenging Disorders of Pigmentation in Skin of Color Heather Woolery-Lloyd, M.D. Director of Ethnic Skin Care Voluntary Assistant Professor Miller/University of Miami School of Medicine Department of Dermatology and Cutaneous Surgery What Determines Skin Color? What Determines Skin Color? No significant difference in the number of melanocytes between the races 2000 epidermal melanocytes/mm2 on head and forearm 1000 epidermal melanocytes/mm2 on the rest of the body differences present at birth Jimbow K, Quevedo WC, Prota G, Fitzpatrick TB (1999) Biology of melanocytes. In I. M. Freedberg, A.Z. Eisen, K. Wolff,K.F. Austen, L.A. Goldsmith, S. I. Katz, T. B. Fitzpatrick (Eds.), Dermatology in General Medicine 5th ed., pp192-220, New York, NY: McGraw Hill Melanosomes in Black and White Skin Black White Szabo G, Gerald AB, Pathak MA, Fitzpatrick TB. Nature1969;222:1081-1082 Jimbow K, Quevedo WC, Prota G, Fitzpatrick TB (1999) Biology of melanocytes. In I. M. Freedberg, A.Z. Eisen, K. Wolff, K.F. Austen, L.A. Goldsmith, S. I. Katz, T. B. Fitzpatrick (Eds.), Dermatology in General Medicine 5th ed., pp192- 220, New York, NY: McGraw Hill Role of Melanin-Advantages Melanin absorbs and scatters energy from UV and visible light to protect epidermal cells from UV damage Disadvantages Inflammation or injury to the skin is almost immediately accompanied by alteration in pigmentation Hyperpigmentation Hypopigmentation Dyschromias Post-Inflammatory hyperpigmentation Acne Melasma Lichen Planus Pigmentosus Progressive Macular Hypomelanosis
    [Show full text]
  • Frequency of Different Types of Facial Melanoses Referring to the Department of Dermatology and Venereology, Nepal Medical Colle
    Amatya et al. BMC Dermatology (2020) 20:4 https://doi.org/10.1186/s12895-020-00100-3 RESEARCH ARTICLE Open Access Frequency of different types of facial melanoses referring to the Department of Dermatology and Venereology, Nepal Medical College and Teaching Hospital in 2019, and assessment of their effect on health-related quality of life Bibush Amatya* , Anil Kumar Jha and Shristi Shrestha Abstract Background: Abnormalities of facial pigmentation, or facial melanoses, are a common presenting complaint in Nepal and are the result of a diverse range of conditions. Objectives: The objective of this study was to determine the frequency, underlying cause and impact on quality of life of facial pigmentary disorders among patients visiting the Department of Dermatology and Venereology, Nepal Medical College and Teaching Hospital (NMCTH) over the course of one year. Methods: This was a cross-sectional study conducted at the Department of Dermatology and Venereology, NMCT H. We recruited patients with facial melanoses above 16 years of age who presented to the outpatient department. Clinical and demographic data were collected and all the enrolled participants completed the validated Nepali version of the Dermatology Life Quality Index (DLQI). Results: Between January 5, 2019 to January 4, 2020, a total of 485 patients were recruited in the study. The most common diagnoses were melasma (166 patients) and post acne hyperpigmentation (71 patients). Quality of life impairment was highest in patients having melasma with steroid induced rosacea-like dermatitis (DLQI = 13.54 ± 1.30), while it was lowest in participants with ephelides (2.45 ± 1.23). Conclusion: Facial melanoses are a common presenting complaint and lead to substantial impacts on quality of life.
    [Show full text]
  • In Dermatology Visit with Me to Discuss
    From time to time new treatments surface for any medical field, and the last couple of years have seen new treatments emerge, or new applications for familiar treatments. I wanted to summarize some of these New Therapies widely available remedies and encourage you to schedule a in Dermatology visit with me to discuss. Written by Board Certified Dermatologist James W. Young, DO, FAOCD Nicotinamide a significant reduction in melanoma in Antioxidants Nicotinamide (niacinamide) is a form high risk skin cancer patients at doses Green tea, pomegranate, delphinidin of vitamin B3. The deficiency of vitamin more than 600 and less than 4,000 IU and fisetin are all under current study for daily. B3 causes pellagra, a condition marked either oral or topical use in the reduction by 4D’s – (photo) Dermatitis, Dementia, Polypodium Leucotomos of the incidence of skin cancer, psoriasis Diarrhea and (if left untreated) Death. and other inflammatory disorders. I’ll be Polypodium leucotomos is a Central This deficiency is rare in developed sure to keep patients updated. countries, but is occasionally seen America fern that is available in several in alcoholism, dieting restrictions, or forms, most widely as Fernblock What Are My Own Thoughts? malabsorption syndromes. Nicotinamide (Amazon) or Heliocare (Walgreen’s and I take Vitamin D 1,000 IU and Heliocare does not cause the adverse effects of Amazon) and others. It is an antioxidant personally. Based on new research, I Nicotinic acid and is safe at doses up to that reduces free oxygen radicals and have also added Nicotinamide which 3,000mg daily. may reduce inflammation in eczema, dementia, sunburn, psoriasis, and vitiligo.
    [Show full text]
  • Psoriasis and Vitiligo: an Association Or Coincidence?
    igmentar f P y D l o is a o n r r d e u r o s J Solovan C, et al., Pigmentary Disorders 2014, 1:1 Journal of Pigmentary Disorders DOI: 10.4172/jpd.1000106 World Health Academy ISSN: 2376-0427 Letter To Editor Open Access Psoriasis and Vitiligo: An Association or Coincidence? Caius Solovan1, Anca E Chiriac2, Tudor Pinteala2, Liliana Foia2 and Anca Chiriac3* 1University of Medicine and Pharmacy “V Babes” Timisoara, Romania 2University of Medicine and Pharmacy “Gr T Popa” Iasi, Romania 3Apollonia University, Nicolina Medical Center, Iasi, Romania *Corresponding author: Anca Chiriac, Apollonia University, Nicolina Medical Center, Iasi, Romania, Tel: 00-40-721-234-999; E-mail: [email protected] Rec date: April 21, 2014; Acc date: May 23, 2014; Pub date: May 25, 2014 Citation: Solovan C, Chiriac AE, Pinteala T, Foia L, Chiriac A (2014) Psoriasis and Vitiligo: An Association or Coincidence? Pigmentary Disorders 1: 106. doi: 10.4172/ jpd.1000106 Copyright: © 2014 Solovan C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Letter to Editor Dermatitis herpetiformis 1 0.08% Sir, Chronic urticaria 2 0.16% The worldwide occurrence of psoriasis in the general population is Lyell syndrome 1 0.08% about 2–3% and of vitiligo is 0.5-1%. Coexistence of these diseases in the same patient is rarely reported and based on a pathogenesis not Quincke edema 1 0.08% completely understood [1].
    [Show full text]
  • Pityriasis Alba Revisited: Perspectives on an Enigmatic Disorder of Childhood
    Pediatric ddermatologyermatology Series Editor: Camila K. Janniger, MD Pityriasis Alba Revisited: Perspectives on an Enigmatic Disorder of Childhood Yuri T. Jadotte, MD; Camila K. Janniger, MD Pityriasis alba (PA) is a localized hypopigmented 80 years ago.2 Mainly seen in the pediatric popula- disorder of childhood with many existing clinical tion, it primarily affects the head and neck region, variants. It is more often detected in individuals with the face being the most commonly involved with a darker complexion but may occur in indi- site.1-3 Pityriasis alba is present in individuals with viduals of all skin types. Atopy, xerosis, and min- all skin types, though it is more noticeable in those with eral deficiencies are potential risk factors. Sun a darker complexion.1,3 This condition also is known exposure exacerbates the contrast between nor- as furfuraceous impetigo, erythema streptogenes, mal and lesional skin, making lesions more visible and pityriasis streptogenes.1 The term pityriasis alba and patients more likely to seek medical atten- remains accurate and appropriate given the etiologic tion. Poor cutaneous hydration appears to be a elusiveness of the disorder. common theme for most riskCUTIS factors and may help elucidate the pathogenesis of this disorder. The Epidemiology end result of this mechanism is inappropriate mel- Pityriasis alba primarily affects preadolescent children anosis manifesting as hypopigmentation. It must aged 3 to 16 years,4 with onset typically occurring be differentiated from other disorders of hypopig- between 6 and 12 years of age.5 Most patients are mentation, such as pityriasis versicolor alba, vitiligo, younger than 15 years,3 with up to 90% aged 6 to nevus depigmentosus, and nevus anemicus.
    [Show full text]
  • Alopecia Areata, Atopic Dermatitis and Vitiligo (Global) Competitive Grant Program - Internal Pfizer Review Process
    Pfizer Announces a Research Grant RFP Alopecia Areata, Atopic Dermatitis and Vitiligo (Global) Competitive Grant Program - internal Pfizer review process I. Background Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP. For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. Alopecia3 Areata, Atopic Dermatitis and Vitiligo (Global) II. Eligibility Geographic Scope: Global (including U.S.A.) Applicant Eligibility • Only organizations are eligible to receive grants, not individuals or Criteria medical practice groups. • The applicant (PI) must have a
    [Show full text]
  • Osteoporosis in Skin Diseases
    International Journal of Molecular Sciences Review Osteoporosis in Skin Diseases Maria Maddalena Sirufo 1,2, Francesca De Pietro 1,2, Enrica Maria Bassino 1,2, Lia Ginaldi 1,2 and Massimo De Martinis 1,2,* 1 Department of Life, Health and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy; [email protected] (M.M.S.); [email protected] (F.D.P.); [email protected] (E.M.B.); [email protected] (L.G.) 2 Allergy and Clinical Immunology Unit, Center for the Diagnosis and Treatment of Osteoporosis, AUSL 04 64100 Teramo, Italy * Correspondence: [email protected]; Tel.: +39-0861-429548; Fax: +39-0861-211395 Received: 1 June 2020; Accepted: 1 July 2020; Published: 3 July 2020 Abstract: Osteoporosis (OP) is defined as a generalized skeletal disease characterized by low bone mass and an alteration of the microarchitecture that lead to an increase in bone fragility and, therefore, an increased risk of fractures. It must be considered today as a true public health problem and the most widespread metabolic bone disease that affects more than 200 million people worldwide. Under physiological conditions, there is a balance between bone formation and bone resorption necessary for skeletal homeostasis. In pathological situations, this balance is altered in favor of osteoclast (OC)-mediated bone resorption. During chronic inflammation, the balance between bone formation and bone resorption may be considerably affected, contributing to a net prevalence of osteoclastogenesis. Skin diseases are the fourth cause of human disease in the world, affecting approximately one third of the world’s population with a prevalence in elderly men.
    [Show full text]
  • RIPE for the PICKING Experts Profile the Future of Biologic Treatments
    RIPE FOR THE PICKING Experts profile the future of biologic treatments 22 DERMATOLOGY WORLD // September 2015 www.aad.org/dw BY VICTORIA HOUGHTON, ASSISTANT MANAGING EDITOR John Harris, MD, PhD, assistant professor of medicine at the University of Massachusetts in the division of dermatology — like many dermatologists — has watched the impressive evolution of treatments for psoriasis over the last decade with anticipation. “We initially had very broad immunosuppressants that were somewhat effective in some patients, but they also had significant side effects,” Dr. Harris said. However, “The onset of biologics and other targeted therapies has been incredible. They’ve revolutionized treatment for psoriasis.” However, while physicians are enthusiastic about the progress of these treatments for psoriasis, there is also hope that interest in developing these innovative therapies is increasingly shifting to other skin conditions. “Pharmaceutical companies have to start looking elsewhere, given how good current psoriasis therapies are,” Dr. Harris said. “The real room for growth is in other diseases.” As psoriasis has paved the way for an interest in developing biologic and other targeted treatments in skin conditions, physicians are anticipating a promising future for these treatments in the following conditions: Atopic dermatitis Hidradenitis suppurativa Chronic urticaria Vitiligo Dermatomyositis >> Alopecia areata DERMATOLOGY WORLD // September 2015 23 RIPE FOR THE PICKING Atopic dermatitis 133; 6:1626-34). The study showed that by blocking the According to Lawrence Eichenfield, MD, professor of immune pathways with CsA, the molecular abnormalities dermatology and pediatrics at the University of California, with AD skin barrier genes, such as filaggrin and loricrin, San Diego and chief of pediatric and adolescent dermatology normalized.
    [Show full text]
  • Case Report Vitiligo Appearing After Oral Isotretinoin Therapy for Acne
    Hindawi Case Reports in Dermatological Medicine Volume 2018, Article ID 3697260, 3 pages https://doi.org/10.1155/2018/3697260 Case Report Vitiligo Appearing after Oral Isotretinoin Therapy for Acne Amal A. Kokandi Department of Dermatology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia Correspondence should be addressed to Amal A. Kokandi; [email protected] Received 15 June 2018; Revised 30 June 2018; Accepted 10 July 2018; Published 12 July 2018 Academic Editor: Jacek Cezary Szepietowski Copyright © 2018 Amal A. Kokandi. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Isotretinoin is an efective treatment for severe and scarring acne. In this report, we describe a case developing vitiligo afer isotretinoin therapy for scarring acne. It is not known whether this was a coincidence or might be precipitated by the treatment. 1. Introduction Afer initial laboratory works (lipid profle and liver enzymes) which were in the normal range, she was started on Isotretinoin is an efective therapy for severe acne. It has the 20 mg isotretinoin. She was maintained on 20 mg (0.5 mg/kg) best infuence on the health-related quality of life in acne for 6 months. She had mild chelitis and skin dryness and patients [1]. Some side efects of isotretinoin are well known complained of mild hair fall. Repeated liver enzymes and lipid and predictable such as chelitis and xerosis. Other side efects profle afer one month and 4 months were within normal are known but less common such as hyperlipidemia.
    [Show full text]
  • Chronic Actinic Damage in Pigmented And
    erimenta xp l D E e r & m l a a t c o i l n o i Journal of Clinical & Experimental Garcia-Romero et al., J Clin Exp Dermatol Res 2012, 3:4 l g y C f R o e DOI: 10.4172/2155-9554.1000154 l ISSN: 2155-9554 s a e n a r r u c o h J Dermatology Research Research Article Open Access Chronic Actinic Damage in Pigmented and Depigmented Skin of Hispanic Patients with Vitiligo: Clinical and Histological Differences Maria Teresa Garcia-Romero1*, Ochoa-Sánchez Patricia Esmeralda1, Díaz-Lozano Marisol2, Toussaint-Caire Sonia2 and Lacy-Niebla Rosa Maria1 1Departamento de Dermatología, Hospital General, Dr. Manuel Gea González, México D.F., México 2Sección de Dermatopatología, Hospital General, Dr. Manuel Gea González, México D.F., México Abstract Vitiligo is a common depigmentary disorder, with loss of epidermal Melanocytes as its hallmark. This absence of melanin hypothetically makes skin more susceptible to Chronic Actinic Damage (CAD) and skin cancer development. However, various studies have shown no increased incidence of skin cancer and some point to decreased actinic damage in skin with vitiligo. We studied 14 patients with vitiligo and analyzed clinical and histological markers of chronic actinic damage both in depigmented skin with vitiligo and in normal skin. We found fewer markers of clinical CAD in depigmented skin than in normally pigmented skin. When we analyzed histological, we found that in most patient’s depigmented skin had increased hyperkeratosis, which is a previously reported finding, as well as atrophy, elastosis and telangiectasias. There are various hypotheses to explain these findings.
    [Show full text]
  • Mucocutaneous Manifestations of Neurofibromatosis Type-1: a Clinical Profile of 51 Indian Patients
    Research Mucocutaneous Manifestations of Neurofibromatosis Type-1: A Clinical Profile of 51 Indian Patients Sudip Kumar Ghosh,1* MD, Debabrata Bandyopadhyay,1 MD, Arghyaprasun Ghosh,1 MD, Sharmila Sarkar,2 M.D Address: 1Department of Dermatology, Venereology & Leprosy, RG Kar Medical College, Kolkata, West Bengal, India and 2Department of Psychiatry, Medical College Calcutta, West Bengal, India E-mail: [email protected] * Corresponding author: Dr. Sudip Kumar Ghosh, Vill + P.O.- Rajballavpur (Via-Maslandpur) Dist.-24 Parganas (N) West Bengal, India Published: J Turk Acad Dermatol 2008; 2 (4):jtad82401a This article is available from: http://www.jtad.org/2008/4/jtad82401a.pdf Key Words: neurofibromatosis type-1, mucocutaneous, neurofibroma, café-au-lait macules Abstract Introduction: Neurofibromatosis (NF) is an autosomal dominant neuro-cutaneous disorder. Eight sub- types of the disease have been proposed till date; neurofibromatosis type –1 (NF1) being the com- monest variety. Objective: Objective of our present study had been to review the prevalence and patterns of muco-cutaneous manifestations amongst patients of NF-1, in a population from eastern India. Methods: This was a clinical, observational, cross sectional study. Results: A total of 51 patients were evaluated. The mean age of the patients was 22.6 years with a male-to-female ratio of 0.7. Positive family history in first-degree relatives was found in 18 (35.3%) pa- tients. Forty-nine patients (96.1%) had neurofibromas including 8 (15.7%) patients of plexiform neu- rofibromas. All of our patients had café-au-lait macules (CALM) and freckling was present in 49 (96.1%) patients.
    [Show full text]
  • Clinical Applications of Psoralens, and Related Materials: Vitiligo—What Is
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE Part V provided by Elsevier - Publisher Connector Clinical Applications of Psoralens, and Related Materials VITILIGO—WHAT IS IT?' HERMANN PINKUS, M.D. 'When I first became interested in vitiligo incourse with and without therapy, and reading connection with psoralen therapy, the answer towhatever could be found in the literature, the the question: what is vitiligo? seemed to be verypicture has become more diversified and even simple. Every textbook gives a clear-cut defini-more puzzling. tion. CLINICAL MORPhOLOGy DEFINITION Concerning the clinical picture and course, it To quote Ormsby-Montgomery (1): "Vitiligois certainly true that most lesions show a com- is an acquired cutaneous achromia characterizedplete absence of pigment and a tendency to by variously sized and shaped single or multipleprogress. However, some patients report that patches of milk white color, usually presentingevery summer, on exposure to sunshine, there is hyperpigmented borders and a tendency tosome repigmentation from the borders, and small enlarge peripherally." The authors add to this:pigmented, freckle-like spots may appear in the "Absence of pigment. .. isthe only symptom incenter of white areas, only to disappear again during the winter. The difference is a real one and vitiligo". .. "Theskin. .. presentsno textural changes and is normal in every way except ais not due to enhanced color contrast between sensitiveness to solar irradiation". .. "thecausetanned and vitiliginous skin in the summer. Re- of vitiligo is unknown". .. "thetreatment of thepigmentation of some degree occurs in 50% of disorder is unsatisfactory". patients according to Lerner (2).
    [Show full text]